<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01042028</url>
  </required_header>
  <id_info>
    <org_study_id>ICE</org_study_id>
    <nct_id>NCT01042028</nct_id>
  </id_info>
  <brief_title>A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer</brief_title>
  <official_title>A Randomised Fase I/II Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Per Pfeiffer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open multicenter randomized phase I/II study. The main purpose with this study is
      to investigate dose and efficacy of a combination of Irinotecan, Cetuximab and Everolimus
      given biweekly to patients with local advanced or metastatic pancreatic cancer AFTER
      progression from 1. line treatment with Gemcitabine.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Emergence of FOLFIRINOX and slow recruitment
  </why_stopped>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Establish maximum tolerable (MTD) dose of ICE (Irinotecan, Cetuximab and Everolimus)</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase I: Determine the maximum tolerated dose (MTD) of ICE in patients with gemcitabine resistant pancreatic cancer</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Progression-free survival as measured from inclusion to either documentation of disease progression or death</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival All events grade 1-5 according to NCI-CTCAE in fase I All Adverse events grade 1-5 according to NCI-CTCAEW in Fase II Correlation between effect of treatment and tumourmarkers Quality of life - EORTC QLQ Time to failure of Strategy</measure>
    <time_frame>22 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Phase II: Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regime A-ICE On progression or unacceptable toxicity patients can cross-over from regime A to regime B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm B: CapOx On progression or unacceptable toxicity patients can cross-over from regime B to regime A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus, Cetuximab, Irinotecan</intervention_name>
    <description>Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage</description>
    <arm_group_label>Phase II: Arm A</arm_group_label>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine, Oxaliplatine</intervention_name>
    <description>Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>Xeloda, Eloxatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained prior to study entry?

          2. Patient has histologically/cytologically proven, non-resectable or metastatic,
             adenocarcinoma of the pancreas?

          3. Progressive disease during adjuvant chemotherapy (or within 6 month after) or
             progressive disease during or after first line chemotherapy?

          4. Former treatment with chemotherapeutic agent containing gemcitabine?

          5. Is the age of the patient ≥ 18 years?

          6. Is the ECOG performance status 0-1?

          7. Is the absolute neutrophil count (ANC) ≥ 1.5 x 109/l?

          8. Is the platelet count ≥ 75 x 109/l?

          9. Is the total bilirubin ≤1.5 x UNL (upper normal limit)?

         10. Patient has normal liver function? (If liver metastases are present, there is no upper
             limit for ALAT/SPGT/alk phosph)?

         11. Creatinine clearance ≥ 30 ml/min

         12. Is the patient capable of following the treatment and the plan of evaluation?

        Exclusion Criteria:

          1. CTC Grade 3 hyperlipidaemia (&gt;10.34 mmol/l) in spite of treatment

          2. Active former or concurrent history of malignant neoplasm, in the last 2 years?

          3. Any condition or therapy which, by the investigators opinion, will expose the patient
             to a risk or will affect the purpose of the clinical trial?

          4. Pregnant or breast feeding patient (fertile patients must use contraceptives)?

          5. Infections or other serious medical conditions, which can obstruct the patient's
             possibility of receiving the treatment? (for instance serious heart, metabolic or lung
             disease)

          6. Known hypersensitivity toward one or more of the parts in the treatment?
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Per Pfeiffer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital, Odense, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Oncology, Aarhus Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2010</study_first_submitted>
  <study_first_submitted_qc>January 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2010</study_first_posted>
  <last_update_submitted>October 18, 2015</last_update_submitted>
  <last_update_submitted_qc>October 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Per Pfeiffer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Pancreas cancer</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Gemcitabine resistant pancreascancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

